Journal
NEURO-ONCOLOGY PRACTICE
Volume 4, Issue 4, Pages 209-219Publisher
OXFORD UNIV PRESS
DOI: 10.1093/nop/npw016
Keywords
bevacizumab; glioma; lomustine; temozolomide; tumor treating fields
Categories
Ask authors/readers for more resources
The therapeutic landscape of the management of low-and high-grade infiltrating gliomas continues to evolve. Daily clinical decision making in neuro-oncology clinics across the US is frequently challenging, especially for anaplastic and low grade primary brain tumors. The focus of this review is centered on treatments which are approved by the FDA and/or featured in the NCCN Guidelines. Systemic therapy trials using a variety of agents such as temozolomide, bevacizumab, and procarbazine, lomustine, vincristine (PCV), and lastly trials of local therapies including surgical trials using carmustine impregnated wafers as well as trials investigating the administration of tumor treating fields are evaluated. Pivotal trials on the treatment of the primary brain tumors are discussed in detail along with associated correlative studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available